{"doi":"10.3390/pathogens13070539","title":"Evaluation of Type I Interferon Treatment in Hospitalized COVID-19 Patients: A Retrospective Cohort Study","abstract":"<jats:p>Coronavirus disease 2019 (COVID-19) continues to cause morbidity and mortality worldwide; therefore, effective treatments remain crucial to controlling it. As interferon-alpha (IFN-α) and -beta (β) have been proposed as COVID-19 treatments, we sought to assess their effectiveness on respiratory, cardiovascular, neurological, and psychiatric signs and symptoms, as well as PASC and death, in hospitalized COVID-19 patients without multiple sclerosis (MS). Using a federated data research network (TriNetX), we performed a retrospective cohort study of hospitalized COVID-19 patients without MS who received IFN-α or -β treatment, comparing them to a similar cohort who did not receive treatment. Following propensity-score matched analyses, we demonstrate that hospitalized COVID-19 patients who were treated with IFN-α or -β had significantly higher odds of death. In contrast, there was no significant difference in any other outcomes between 1–30 days or 1 day to anytime afterward. Overall, hospitalized COVID-19 patients without MS who were treated with IFN-α or -β had similar short- and long-term sequelae (except for mortality) as those who did not receive treatment. The potential benefits of utilizing IFN-α or -β treatment as therapeutics remain to be realized, and our research highlights the need to explore repurposing drugs for COVID-19 using real-world evidence.</jats:p>","journal":"Pathogens","year":2024,"id":609774,"datarank":0.16479184330021646,"base_score":1.0986122886681096,"endowment":1.0986122886681096,"self_citation_contribution":0.16479184330021646,"citation_network_contribution":0.0,"self_endowment_contribution":0.16479184330021646,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":2,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1176453,"name":"Pinghan Huang","orcid":"0000-0003-2460-0695","position":1,"is_corresponding":false},{"id":275505,"name":"Kamil Khanipov","orcid":"0000-0002-3881-737X","position":2,"is_corresponding":false},{"id":1567451,"name":"Nathan Y. Tat","orcid":"0009-0008-7764-1427","position":3,"is_corresponding":false},{"id":1567452,"name":"Chien-Te Kent Tseng","orcid":null,"position":4,"is_corresponding":false},{"id":275501,"name":"George Golovko","orcid":"0000-0003-4609-2767","position":5,"is_corresponding":false},{"id":1567450,"name":"Vivian Y. Tat","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Evaluation of Type I Interferon Treatment in Hospitalized COVID-19 Patients: A Retrospective Cohort Study","abstract":"<jats:p>Coronavirus disease 2019 (COVID-19) continues to cause morbidity and mortality worldwide; therefore, effective treatments remain crucial to controlling it. As interferon-alpha (IFN-α) and -beta (β) have been proposed as COVID-19 treatments, we sought to assess their effectiveness on respiratory, cardiovascular, neurological, and psychiatric signs and symptoms, as well as PASC and death, in hospitalized COVID-19 patients without multiple sclerosis (MS). Using a federated data research network (TriNetX), we performed a retrospective cohort study of hospitalized COVID-19 patients without MS who received IFN-α or -β treatment, comparing them to a similar cohort who did not receive treatment. Following propensity-score matched analyses, we demonstrate that hospitalized COVID-19 patients who were treated with IFN-α or -β had significantly higher odds of death. In contrast, there was no significant difference in any other outcomes between 1–30 days or 1 day to anytime afterward. Overall, hospitalized COVID-19 patients without MS who were treated with IFN-α or -β had similar short- and long-term sequelae (except for mortality) as those who did not receive treatment. The potential benefits of utilizing IFN-α or -β treatment as therapeutics remain to be realized, and our research highlights the need to explore repurposing drugs for COVID-19 using real-world evidence.</jats:p>","is_dataset_classified":null,"base_score":1.0986122886681096,"endowment":1.0986122886681096,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"39057766","pmcid":"PMC11280121","openalex_id":"https://openalex.org/W4400038139","authors":[],"funders":[{"funder_name":"Institute for Translational Sciences at The University of Texas Medical Branch","grant_id":"UL1TR001439","title":null},{"funder_name":"Institute for Translational Sciences at The University of Texas Medical Branch","grant_id":"U01AI151801","title":null},{"funder_name":"National Institutes of Health","grant_id":"5UL1TR001439-07","title":"UTMB Clinical and Translational Science Award"},{"funder_name":"National Institutes of Health","grant_id":"5U01AI151801-04","title":"West African Center for Emerging Infectious Diseases"}],"total_grants":4,"fwci":0.5524,"citation_percentile":0.66033777,"influential_citations":0,"citation_trend":[{"year":2025,"count":2}],"oa_status":"gold","license":"cc-by","oa_locations":[{"url":"https://www.mdpi.com/2076-0817/13/7/539/pdf?version=1719397086","host_type":"journal"},{"url":"https://www.mdpi.com/2076-0817/13/7/539/pdf?version=1719397086","host_type":"publisher"},{"url":"https://www.mdpi.com/2076-0817/13/7/539/pdf","host_type":"publisher"},{"url":"https://doi.org/10.3390/pathogens13070539","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/39057766","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/11280121","host_type":"repository"},{"url":"https://doaj.org/article/4c5b0cd6e462432b85e1e28a514304ef","host_type":"repository"},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11280121/pdf/pathogens-13-00539.pdf","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC11280121","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC11280121?pdf=render","host_type":"Europe_PMC"},{"url":"https://doi.org/10.20944/preprints202405.1544.v1","host_type":""},{"url":"http://dx.doi.org/10.3390/pathogens13070539","host_type":""},{"url":"https://dx.doi.org/10.3390/pathogens13070539","host_type":""}],"fields_of_study":["Long-Term Effects of COVID-19","COVID-19 Clinical Research Studies","SARS-CoV-2 and COVID-19 Research","0301 basic medicine","03 medical and health sciences","0303 health sciences","Humans","Retrospective Studies","Male","Female","Middle Aged","COVID-19 Drug Treatment","SARS-CoV-2","COVID-19","Hospitalization","Antiviral Agents","Aged","Adult","Interferon Type I","Interferon-alpha","Interferon-beta","Treatment Outcome"],"mesh_terms":["COVID-19","SARS-CoV-2","COVID-19 Drug Treatment","Adult","Aged","Antiviral Agents","Female","Hospitalization","Humans","Interferon Type I","Male","Middle Aged","Retrospective Studies","Treatment Outcome","Interferon-alpha","Interferon-beta"],"keywords":["Retrospective cohort study","Medicine","Coronavirus disease 2019 (COVID-19)","Cohort","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","Virology","2019-20 coronavirus outbreak","Interferon","Cohort study","Internal medicine","Disease","Outbreak","Infectious disease (medical specialty)","Interferons","Treatments","Sequelae","Covid-19","Male","Adult","Medicine and Pharmacology","Antiviral Agents","Article","Humans","Retrospective Studies","Aged","SARS-CoV-2","Epidemiology and Infectious Diseases","R","Interferon-alpha","Interferon-beta","Middle Aged","COVID-19 Drug Treatment","Hospitalization","Treatment Outcome","Interferon Type I","Female"],"sdg_mappings":[{"sdg_number":3,"sdg_label":"3. Good health"},{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-31T15:03:14.644492Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}